Evidence map›Paper›PMID 38862540›Full record

ArticleNature communications2024

iPS cell generation-associated point mutations include many C > T substitutions via different cytosine modification mechanisms.

Ryoko Araki, Tomo Suga, Yuko Hoki, Kaori Imadome, Misato Sunayama, Satoshi Kamimura, Mayumi Fujita, Masumi Abe

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ryoko ArakiStem Cell Biology Team, Institute for Quantum Life Science, National Institutes for Quantum Science and Technology, Chiba, Japan. araki.ryoko@qst.go.jp.ORCID http://orcid.org/0000-0003-3972-3153
Tomo SugaStem Cell Biology Team, Institute for Quantum Life Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Yuko HokiStem Cell Biology Team, Institute for Quantum Life Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Kaori ImadomeStem Cell Biology Team, Institute for Quantum Life Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Misato SunayamaStem Cell Biology Team, Institute for Quantum Life Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Satoshi KamimuraStem Cell Biology Team, Institute for Quantum Life Science, National Institutes for Quantum Science and Technology, Chiba, Japan.ORCID http://orcid.org/0000-0002-5615-2674
Mayumi FujitaStem Cell Biology Team, Institute for Quantum Life Science, National Institutes for Quantum Science and Technology, Chiba, Japan.ORCID http://orcid.org/0000-0001-5230-4573
Masumi AbeInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan. abe.masumi@qst.go.jp.ORCID http://orcid.org/0000-0003-1550-2006

Funding

Japan Agency for Medical Research and Development (AMED) JP23zf0127008MEXT | Japan Society for the Promotion of Science (JSPS) KAKENHI 21H02689Wellcome Trust
6 · The paper itself

Abstract

Genomic aberrations are a critical impediment for the safe medical use of iPSCs and their origin and developmental mechanisms remain unknown. Here we find through WGS analysis of human and mouse iPSC lines that genomic mutations are de novo events and that, in addition to unmodified cytosine base prone to deamination, the DNA methylation sequence CpG represents a significant mutation-prone site. CGI and TSS regions show increased mutations in iPSCs and elevated mutations are observed in retrotransposons, especially in the AluY subfamily. Furthermore, increased cytosine to thymine mutations are observed in differentially methylated regions. These results indicate that in addition to deamination of cytosine, demethylation of methylated cytosine, which plays a central role in genome reprogramming, may act mutagenically during iPSC generation.

Indexed as

CpG IslandsCytosineDNA MethylationInduced Pluripotent Stem CellsPoint MutationAnimalsCell LineCellular ReprogrammingHumansMiceRetroelementsCytosineRetroelements

Identifiers

PMID38862540
PMCPMC11166658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.